Navigation Links
Insmed Announces First Quarter 2008 Financial Results
Date:5/8/2008

Adjustments to reconcile net loss to net cash

used in operating activities:

Depreciation and amortization 292 82

Stock based compensation expense 133 56

Stock options issued for services - 8

Changes in operating assets and liabilities:

Accounts receivable (77) 130

Inventory - 576

Other assets 134 52

Accounts payable (100) (2,936)

Accrued project costs 12 (547)

Payroll liabilities 168 812

Deferred income 26 -

Asset retirement obligation - 147

Interest payable (3) -

Net cash used in operating activities (4,288) (11,873)

Investing activities

Decreases (increases) of short-term investments 5,601 12,044

Purchases of investments - (500)

Realized loss on investments 392 -

Net cash provided by investing activities 5,993 11,544

Financing activities

Repayment of convertible notes (553) -

Cash restricted to restricted letters of credit - 297

Net cash (used in) provided by financing activities (553) 297

Increase (decrease) in cash and cash equivalents 1,152 (32)

Cash and cash equivalents at beginning of period 3,554 2,121

Cash and cash equivalents at end of period $4,70
'/>"/>

SOURCE Insmed Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Insmed Appoints Dennis M. Lanfear to Board Of Directors
2. Insmed Awarded $2.1 Million by Muscular Dystrophy Association
3. Insmed to Appeal Delisting Notification From Nasdaq
4. Insmed President Interviewed for Follow-On Biologics Podcast: Insmed Inc. President Steve Glover Discusses Safe and Effective Biologic Therapies and Reduced Costs with The American Magazine
5. Insmed CEO Issues Statement on White House FY09 Budget and FDA Statements on Follow-On Biologics
6. Insmed to Host Fourth Quarter and Full-Year 2007 Conference Call
7. Insmed Announces Listing Transfer from Nasdaq Global Market to Nasdaq Capital Market
8. Insmed Announces Fourth Quarter and Full-Year 2007 Financial Results
9. Insmed Announces Additional Information in Compliance With NASDAQ Rules
10. Insmed Selected to Complete Congressional Questionnaire Regarding the Potential Establishment of a Follow-On Biologics Regulatory Pathway
11. Insmed to Present at CBI Follow-On Biologics Conference

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/6/2009)... , The agenda for Arrowhe... Conference, which is set to take place on Februar... At this three day conference we will highlight ke...st speakers to share their experiences. , ...6, 2009 -- The agenda for Arrowhead’s 2010 ...
(Date:11/5/2009)... , PARSIPPANY, N.J., Nov. 5 D... has made a manufacturing alliance with Galenix, S...referred commercial scale manufacturing partner fo..., DSM and Galenix will collaborate on business ...g delivery technologies, based on the strength of ...
(Date:11/5/2009)... , OMAHA, Neb., Nov. 5 /PRNewswire-FirstCall/...today announced financial results for the quarter ...results are presented in the tables that follow. ,...ed a net loss of $366,000 or $0.01 per share for t... of $499,000 or $0.01 per share for the third quar...
(Date:11/5/2009)... , SAN DIEGO, CA, November 5, 2009 /PRNewswir...company focused on using proprietary taste recepto...edients for the food, beverage, and ingredient sup...and reported financial results for the third quart...illion for the third quarter of 2009, compared to ...
Breaking Biology Technology:Leaders in Biopharma and Molecular Diagnostics to Discuss Key Issues and Opportunities in Forming Partnerships at 2010 Personalized Medicine Partnerships Conference 2Leaders in Biopharma and Molecular Diagnostics to Discuss Key Issues and Opportunities in Forming Partnerships at 2010 Personalized Medicine Partnerships Conference 3DSM Pharmaceutical Products Forms Manufacturing Alliance With Galenix 2DSM Pharmaceutical Products Forms Manufacturing Alliance With Galenix 3Transgenomic, Inc. Reports Third Quarter 2009 Results 2Transgenomic, Inc. Reports Third Quarter 2009 Results 3Transgenomic, Inc. Reports Third Quarter 2009 Results 4Transgenomic, Inc. Reports Third Quarter 2009 Results 5Transgenomic, Inc. Reports Third Quarter 2009 Results 6Transgenomic, Inc. Reports Third Quarter 2009 Results 7SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 2SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 3SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 4SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 5SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 6SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 7SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 8SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 9SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 10SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 11SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 12SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 13SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 14
...cology clinical development solutions in North Ame...il 17 SIRO ClinPharm (SIRO), a leading multinat...announced the signing of a strategic alliance with...ons), Flemington, NJ, USA, a service provider in o...tion in North America. This alliance will enable ...
...v, a global chemistry-driven contract research org...ech Center has acquired Prudentas LLC, one of the ...e I - Phase IV studies in Eastern Europe. Prudenta...siness name Prudentas LLC, a ChemDiv Group compan...ed with Prudentas, who established itself as an ex...
...electronic information from old cassette tapes to... the electronics industry for decades. , Low-powe...long-term result of collaborative research led by ...search, to be published April 17 in the journal S...l-known oxide, strontium titanate, and depositing ...
Other Biology Technology:SIRO ClinPharm and Advanced Clinical Trial Solutions Ink Strategic Alliance 2ChemDiv Group Acquires Prudentas Through ChemRar High Tech Center 2ChemDiv Group Acquires Prudentas Through ChemRar High Tech Center 3Putting the squeeze on an old material could lead to 'instant on' electronic memory 2
(Date:11/4/2009)... Calif., Oct. 19 Spectros, develop...and imaging devices which shed light on life-threa...d exclusive distribution deals for both its T-Stat...ts covered include Australia, New Zealand, The Ne..., Italy, France, Spain, Portugal, Poland, Greece, ...
(Date:11/4/2009)... Oct. 20 Aware, Inc. (Na...hnology and biometrics software, today reported fi...mber 30, 2009. ,, Michael Tzannes, Aware,s Ch... today, we announced an agreement to sell our DSL ... fabless semiconductor company being spun out of I...
(Date:11/4/2009).... 26 BIO-key Internation...inger-based biometric identification software is s...the AABB TXPO conference being held at the New Orl...O-key will provide hands-on product demonstrations... in booth #424. Also, at 5 PM on Monday, October 2...
Breaking Biology News(10 mins):Spectros Signs New International Distribution Deals 2Aware, Inc. Reports Third Quarter 2009 Financial Results 2Aware, Inc. Reports Third Quarter 2009 Financial Results 3Aware, Inc. Reports Third Quarter 2009 Financial Results 4Aware, Inc. Reports Third Quarter 2009 Financial Results 5Aware, Inc. Reports Third Quarter 2009 Financial Results 6Aware, Inc. Reports Third Quarter 2009 Financial Results 7BIO-key(R) International Exhibiting at AABB TXPO 2In Health Care Today Its Electronic All the Way 58815 1In Health Care Today Its Electronic All the Way 58815 2In Health Care Today Its Electronic All the Way 58815 3Park Meadows Cosmetic Surgery a Leader in Breast Reconstruction Surgery Recognizes National Breast Cancer Awareness Month 58813 1Park Meadows Cosmetic Surgery a Leader in Breast Reconstruction Surgery Recognizes National Breast Cancer Awareness Month 58813 2Park Meadows Cosmetic Surgery a Leader in Breast Reconstruction Surgery Recognizes National Breast Cancer Awareness Month 58813 331 Breast Cancer Myths 26amp 3B Truths in 31 Days 58811 131 Breast Cancer Myths 26amp 3B Truths in 31 Days 58811 2
...release is available in French . Montreal, 13...ealth Centre (MUHC), McGill University and the Uni...medical use of cannabinoids do not cause an increa...ith an increase in some non-serious adverse events...rom the cannabis plant, or cannibinoids, are avail...
...towers Institute,s Rong Li Lab has discovered that...ammation may also have a role in the formation of ...ase (ADPKD) one of the most common life-threateni...ibiting the protein can slow the disease in mice. ...nline publication of Nature Medicine yesterday. ...
...ANCISCO, CA June 16, 2008 --- iZumi Bio, Inc. and... non-profit biomedical research organization, have...nsing agreement to focus on applications for induc... "reprogrammed" adult cells that have similar prop...tem (ES) cells, yet do not raise the same ethical ...
Other Biology News:Medicines derived from cannabis: a review of adverse events 2Rong Li Lab identifies new role of inflammatory protein in PKD and a possible treatment 2
Feature Extraction Software; 1-year license for Commercial from Agilent Technologies
...tem from Molecular Devices provides precise dispen...he system handles a variety of plate formats for d...and is the first to handle 1536-well microplate wa...from four different channels to accommodate up to ...
Dithiothreitol from USB Corp.
...various commercial and lab-prepared glass arrays. ...ntent of the attached nucleic acid targets, and th...e optimal hybridization conditions for glass micro...to consider, it is impossible for one hybridizatio...
Biology Products: